

Alpha Stem Cell Clinics Trials



The Alpha Stem Cell Clinics Network is pursuing its goal to accelerate the development and delivery of stem cell treatments to patients through high quality clinical trials.


Browse the list of ongoing trials at Alpha Stem Cell Clinic locations in the table below. You can sort trials based on different fields by clicking on the appropriate column header. Trials are automatically listed by status of trial enrollment and Alpha Clinic location.

Alpha Clinic Trials

Alpha Clinic ▲	Alpha Clinic Contact	Trial Sponsor	Disease Indication	Clinical Trial Name	Status of Enrollment	Learn More
UCI & UCSD & UC Davis	UCI Stem Cell Clinic 949-824-3990 stemcell@uci.edu Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu	Aivita Biomedical	Cancer - Brain	Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma	Recruiting	
UCI	UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu	Stratetech	Burn wounds	StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements	Active, not recruiting	
UCI	Breana Chew 949-824-8116 chewbc@hs.uci.edu	Brain Neurotherapy Bio	Parkinson's	Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson's Disease	Recruiting	
UCI	UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu	jCyte	Eye - Retinitis Pigmentosa (RP)	Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa	No longer active	
UCI	Jennifer Scott 714-456-5956 scottj2@uci.edu	Pluristem Ltd.	Intubated COVID-19 patients	A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19	Recruiting	
UCI & UC Davis	UCI: Jennifer Scott 714-456-4956 scottj2@uci.edu UC Davis: Kate Trigg 916-734-8033 ktrigg@ucdavis.edu	Celularity, Inc.	Hospitalized COVID-19 patients	A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19	Recruiting	

UCI	UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu	BrainStorm Cell Therapeutics	Amyotrophic Lateral Sclerosis (ALS)	A phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate efficacy and safety of repeated administrations of NurOwn® (autologous mesenchymal stem cells secreting neurotrophic factors) in participants with ALS	Recruiting	
UCI & UC Davis	UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu UC Davis: Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu	Humacyte	Kidney Failure	An Assessment of Humacyte's Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison With ePTFE Grafts as Conduits for Hemodialysis (HUMANITY)	Active, not recruiting	
UCI	UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu	ImmunoCellular Therapeutics	Cancer - Brain	A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma	No longer active	
UCI & UC Davis	UCI Stem Cell Clinic: Roy Fujitani 949-824-3990 stemcell@uci.edu	Humacyte	Kidney failure	A Phase 3 Study to Compare the Efficacy and Safety of Humacyte's Human Acellular Vessel With That of an Autologous Arteriovenous Fistula in Subjects With End Stage Renal Disease	Recruiting	
UCI	UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu	SanBio	Stroke	Study of Modified Stem Cells in Patients With Chronic Motor Deficit From Ischemic Stroke	No longer active	
UCI	UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu	Pluristem Ltd.	Critical Limb Ischemia (CLI)	A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Phase III Study to Evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX-PAD for the Treatment of Subjects with Critical Limb Ischemia (CLI) with Minor	Recruiting	
UCI	UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu	ReNeuron Limited	Stroke	A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTXoE03) in Subjects with Disability Following an Ischemic Stroke (PISCES III)	Recruiting	
UCI	UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu	Longeveron	Aging frailty	Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty	Active, not recruiting	
UCSD	UCSD Stem Cell Clinic (844) 317-7836 alphastemcellclinic@ucsd.edu	Persimmune, Inc.	Cancer - Blood	Collection of Bone Marrow, Peripheral Blood (PB), Epithelial Tissue, and Saliva Samples From Patients With Myelodysplastic Syndromes (MDS) to Identify MDS-Specific Antigens	Recruiting	
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Viacyte	Diabetes - Type 1	A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus	Recruiting	

UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	UCSD	Cancer - Leukemia	UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia	No longer active	
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Mesoblast	Heart Failure	The Purpose of This Study is to Evaluate the Efficacy and Safety of a Allogeneic Mesenchymal Precursor Cells (CEP-41750) for the Treatment of Chronic Heart Failure	Recruiting	
UCSD & City of Hope	(844) 317-7836 alphastemcellclinic@ucsd.edu	UCSD	Cancer - Leukemia	A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies	Recruiting	
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Viacyte	Diabetes - Type 1	A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness	Recruiting	
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Persimmune, Inc.	Cancer - Blood	Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN)	Recruiting	
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Neuralstem	Spinal Cord Injury	Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI	Recruiting	
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	UCSD	Cancer - Leukemia	Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961	No longer active	
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Viacyte	Diabetes - Type 1	Three Year Follow-up Safety Study in Subjects Previously Implanted With VC-01	Recruiting	
UCSD	Barbara Parker, MD 858-822-6135 baparker@ucsd.edu Rebecca Shatsky, MD 858-657-7000 rshatsky@ucsd.edu	UCSD	Cancer - Breast	Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer	Recruiting	
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Asterias Biotherapeutics	Spinal Cord Injury	Dose Escalation Study of AST-OPC1 in Spinal Cord Injury	No longer active	
UCSD	Teresa Rzesiewicz 844-317-7836 alphastemcellclinic@ucsd.edu	Discgenics	Degenerative Disc Disease	Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration	Recruiting	
UCLA	Caroline Kuo, MD 310-794-1940 ckuo@mednet.ucla.edu	UCLA	X-linked Chronic Granulomatous Disease	Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease	Recruiting	
UCLA	Maricela Gonzalez (310) 557-3729 mmgonzalez@mednet.ucla.edu	Calimmune	HIV/AIDS	Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection	No longer active	

UCLA	Scott Nowicki, MD, PhD Ignacio Baselga Carretero, PhD 310-206-2090 lbaselga@mednet.ucla.edu	UCLA	Cancer - Solid Tumors	Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies	Recruiting	
UCLA & UCI	UCLA: Courtney Real, BSN 310-267-7433 creal@mednet.ucla.edu UCI: UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu	SanBio	Brain Injury	A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI)	Active, not recruiting	
UCLA	Lia Etheridge (310)-825-7174 letheridge@mednet.ucla.edu	UCLA	Cancer - Lung	A Phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC	Recruiting	
UCLA	Kit L Shaw, PhD (310) 267-0584 kshaw@mednet.ucla.edu	Orchard Therapeutics	Severe Combined Immunodeficiency (SCID)	Efficacy and Safety of a Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With EFS Lentiviral Vector Encoding for Human ADA Gene in Subjects With ADA Deficiency Severe Combined Immunodeficiency	Active, not recruiting	
UCLA	Kit L Shaw, PhD (310) 267-0584 kshaw@mednet.ucla.edu	UCLA	Severe Combined Immunodeficiency (SCID)	Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID)	No longer active	
UCLA	Sarah Larson, MD 310-206-8477 slarson@mednet.ucla.edu	UCLA	Cancer	TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM)	No longer active	
UCLA	Fabrizia Urbinati, PhD (310) 794-1884 furbinati@ucla.edu	UCLA	Sickle Cell Disease	Stem Cell Gene Therapy for Sickle Cell Disease	Recruiting	
City of Hope	Karen Reckamp, MD (626) 256-4673 x89200 kreckamp@coh.org	Adaptimmune	Cancer - Lung	Screening Protocol for Tumor Antigen Expression and HLA Sub-Type in NSCLC	Recruiting	
City of Hope	Mihaela Cristea, MD (626) 256-4673 x89200 mcristea@coh.org	Adaptimmune	Cancer - Ovarian	A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.	Recruiting	

City of Hope	Hormoz Babaei Mirshkarlo 626-218-8074 hmirshkarlo@coh.org	Celgene	Cancer - Lymphoma	An Exploratory Phase 1/2 Trial to Evaluate the Safety and Efficacy of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies (PLATFORM)	Recruiting	
City of Hope	Warren Chow, MD (626) 256-4673 x89200 wchow@coh.org	Adaptimmune	Cancer - Sarcoma	A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma	Active, not recruiting	
City of Hope	Teresa Kim 626-218-0263 teresakim@coh.org	City of Hope	Sickle Cell Disease	A Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients with COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant	Recruiting	
City of Hope	Behnam Badie, MD: 626-256-4673 bbadie@coh.org	City of Hope	Cancer - Brain	Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma	Recruiting	
City of Hope	Nadia Ewing, MD (626) 256-4673 x89200 newing@coh.org	Sangamo Therapeutics	Hemophilia B	Ascending Dose Study of Genome Editing by the Zinc Finger Protein (ZFP) Therapeutic SB-FIX in Subjects With Severe Hemophilia B	Recruiting	
City of Hope	Cara Nolan 626-218-3241 canolan@coh.org	Juno Therapeutics	Cancer - Lymphoma	An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)	Recruiting	
City of Hope	Myo Htut, MD 626-218-2405 ext 82405 mhtut@coh.org	Juno Therapeutics	Cancer - Myeloma	Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE)	Recruiting	
City of Hope	Cara Nolan 626-256-4673 ext 32341 cnolan@coh.org	Juno Therapeutics	Cancer - Lymphoma	Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL)	Recruiting	
City of Hope	Joseph Rosenthal, MD 626-256-4673 ext 88442 jrosenthal@coh.org	City of Hope	Sickle Cell Disease	Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease (PISMO)	Recruiting	
City of Hope	Hormoz Mirshkarlo 626-218-8074 hmirshkarlo@coh.org	Kite Pharma	Cancer - Lymphoma	A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6)	Recruiting	
City of Hope	Lucy Ghoda 626-218-3605 lghoda@coh.org	City of Hope	Neurodegenerative Disorder	Acquisition of Skin Biopsy Samples from Healthy Volunteers and Patients Diagnosed with X-Linked Adrenoleukodystrophy (ALD), Canavan Disease (CD) and other Inherited Leukodystrophies	Recruiting	

City of Hope	Fatemeh Bidmeshki 626-218-9393 fbidmeshki@coh.org	City of Hope	Cancer - Brain	HER2-CAR T Cells in Treating Participants With Brain or Leptomeningeal Metastases	Recruiting	

1 2 3 next > last >>

Clinical trials conducted at CIRM Alpha Stem Cell Clinics must comply with applicable federal and state laws and medical and ethical standards governing the conduct of human clinical trials.

Find Out More:

About Alpha Stem Cell Clinics

Alpha Clinics News

Source URL: https://www.cirm.ca.gov/patients/alpha-clinics-network/alpha-clinics-trials?order=field_alpha_clinic&sort=asc